CLDX (celldex.com) Market Value to Book Value Ratio
The prospects for Celldex Therapeutics (CLDX) rely on antibody trials for dermatitis, where stage-related risks are mitigated by strong data, allowing capital to be maintained at 3.22. The success of Barzolvolimab against urticaria promises immense margins driven by patents. This price trajectory shown below illustrates the dynamics of a biotech company whose drug delivery is based on strict temperature control to preserve drug activity.
%3A%20Market%20Capitalization%20to%20Net%20Assets&width=1200&height=400&colorIndex=0&v=mvq8bmkb.8d-7aozthc&start=20220704&end=20261027&filename=GURU_Markets_-_CLDX_-_Celldex-Therapeutics_-_Market-Capitalization-to-Net-Assets "CLDX Celldex Corp Market Capitalization to Book Value Ratio (07/04/2022 - 10/27/2026) | 👁️GURU.Markets👁️")
Financial and market metric breakdowns for Celldex Therapeutics Inc (CLDX)
- price and consensus price forecast:
- market capitalization data:
- book capitalization data:
- debt and liquidity data:
Initial company analysis:Celldex Therapeutics - CLDX
This indicator compares the current market value of Celldex Therapeutics (CLDX) with its net assets, allowing for the rapid identification of the gap between speculative pricing and actual capital. Analyzing the price-to-book ratio helps filter out market noise and determine trend reversal phases, which is critical when assessing the risks of the company's diversified portfolio of monoclonal antibody clinical trials.
Main competitors
Market Cap to Net Assets Ratio argenx SE|BNTX (biontech.de) - Capitalization to Book Value Ratio|Market Value to Book Value Ratio abivax.com ABVX|Market Capitalization to Net Assets ADMA Biologics Inc|Protagonist Therapeutics Inc (PTGX) - Market Capitalization to Book Value Ratio|Market Value to Book Value Immunovant Therapeutics (IMVT)|Market Capitalization to Book Value Ratio KNSA (Kiniksa Pharmaceuticals)|grifols.com - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Adaptive Biotechnologies Corporation (ADPT)|AUPH: Market Value to Book Value|BCRX (BioCryst Pharmaceuticals Inc) - Market Value to Book Value Ratio|Vera Corp (VERA) - Market Cap to Net Assets Ratio|DNTH (Dianthus Therapeutics) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio pharvaris.com (PHVS)|AbCellera Bio (ABCL) - Market Cap to Net Assets Ratio|Market Value to Book Value Tourmaline Bio Inc (TRML)|Market Capitalization to Book Value Ratio PGEN|Pharming Corp - Market Capitalization to Book Value|NKTR: Market Value to Book Value Ratio|UPB: Market Cap to Net Assets Ratio|ZBIO (Zenas Biopharma) - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio Immunome Inc|GOSS (Gossamer Corp) - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio KALV|Market Value to Book Value Ratio Septerna Inc SEPN|Capitalization to Book Value Ratio pieris.com (PVLA)|SVRA: Market Capitalization to Book Value Ratio|Market-to-Book Ratio Rigel Pharma RIGL|ANAB: Market Capitalization to Book Value Ratio|ATXS - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio ENGN|RAPT (rapt.com) - Market-to-Book Ratio|Market Value to Book Value Ratio Aerovate Therapeutics, Inc.|Market Value to Book Value Ratio ACRS|Market Value to Book Value Ratio Kyverna (KYTX)|Market Value to Book Value Ratio Tiziana Life Sciences, Ltd. (TLSA)|CABA - Market Capitalization to Book Value Ratio|Capitalization to Book Value Ratio ventyxbio.com VTYX|THTX (Theratechnologies) - Market Capitalization to Book Value Ratio|Avalo Therapeutics, Inc. (AVTX) - Market-to-Book Ratio|Market Cap to Net Assets Ratio Eledon|Capitalization to Book Value Ratio Agenus, Inc|CLYM - Market Cap to Net Assets Ratio|Market Value to Book Value zurabio.com (ZURA)|Market Cap to Net Assets Ratio aTyr Pharma|Market Cap to Book Value Multiple adagene.com (ADAG)|Market Capitalization to Book Value Ratio Ikena Oncology|Market Value to Book Value Shattuck Labs Inc STTK|EQ (Equillium Bio) - Market Capitalization to Book Value Ratio|CNTB: Market-to-Book Ratio|Market Value to Book Value Ratio immunic-therapeutics.com IMUX|Atara Bio (ATRA) - Market Value to Book Value|IFRX (InflaRx NV) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio XFOR|ACET - Market Value to Book Value Ratio|Market Capitalization to Net Assets celularity.com (CELU)|INMB: Market Capitalization to Book Value Ratio|BRNS - Market-to-Book Ratio|Kezar Life Sciences, Inc - Market Cap to Net Assets Ratio|SAB Biotherapeutics Inc (SABS) - Market Capitalization to Book Value Ratio|AKTX - Market Cap to Net Assets Ratio|Enlivex Therapeutics Ltd. (ENLV) - Market Cap to Book Value Multiple|QTTB: Market Capitalization to Book Value Ratio|Market Capitalization to Book Value GeoVax Labs|Market Capitalization to Book Value Ratio EDSA (Edesa)|Market Cap to Net Assets Ratio IBIO (iBio Corporation)|Market Value to Book Value Ratio CARM|Market Capitalization to Book Value xtlbio.com XTLB|BOLT: Market Capitalization to Book Value Ratio|HCWB: Market Cap to Net Assets Ratio|aptevotherapeutics.com (APVO) - Market Value to Book Value Ratio|aimimmuno.com (AIM) - Market Value to Book Value Ratio|Market Capitalization to Book Value Ratio Aditxt Inc. (ADTX)|Capitalization to Book Value Ratio gribio.com (GRI)|Market Cap to Net Assets Ratio XORTX Therapeutics XRTX|Capitalization to Book Value Ratio HIND (Vyome Holdings Inc.)|Revelation Bio (REVB) - Market Value to Book Value Ratio|Market Capitalization to Net Assets Indaptus Corp INDP|Market Capitalization to Book Value Ratio Scinai Immunotherapeutics (SCNI)|CALI - Market Value to Book Value|AFMD: Market Capitalization to Book Value Ratio|ALLK (Allakos) - Market Capitalization to Book Value Ratio|HOOK - Market Value to Book Value Ratio|Market Value to Book Value IGMS|Market Value to Book Value Ratio ITOS (iTeos Therapeutics)|Market Cap to Net Assets Ratio oceanbiomedical.com (OCEA)|Market Capitalization to Book Value Ratio TCBP (TC BioPharm)|THRD - Market Capitalization to Book Value Ratio